Stockscreener 앱 받기
2.22
0.45%
-0.010
시간 외 거래:
2.25
0.03
+1.35%
전일 마감가:
$2.23
열려 있는:
$2.24
하루 거래량:
491.70K
Relative Volume:
0.57
시가총액:
$141.38M
수익:
-
순이익/손실:
$-30.92M
주가수익비율:
-3.6822
EPS:
-0.6029
순현금흐름:
$-27.39M
1주 성능:
+6.73%
1개월 성능:
-3.90%
6개월 성능:
+155.17%
1년 성능:
-9.39%
1일 변동 폭
$2.19
$2.38
1주일 범위
$2.07
$2.4843
52주 변동 폭
$0.41
$3.90
Tuhura Biosciences Inc Stock (HURA) Company Profile
명칭
Tuhura Biosciences Inc
전화
813-875-6600
주소
10500 UNIVERSITY CENTER DR., TAMPA
Compare HURA vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HURA
Tuhura Biosciences Inc
|
2.22 | 144.56M | 0 | -30.92M | -27.39M | -0.6029 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tuhura Biosciences Inc Stock (HURA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-27 | 개시 | Citizens | Mkt Outperform |
| 2025-03-03 | 개시 | H.C. Wainwright | Buy |
| 2024-12-19 | 개시 | Rodman & Renshaw | Buy |
| 2024-11-05 | 개시 | Maxim Group | Buy |
Tuhura Biosciences Inc 주식(HURA)의 최신 뉴스
Citizens reiterates TuHURA Biosciences stock rating on AML progress By Investing.com - Investing.com Canada
TuHURA Biosciences (NASDAQ:HURA) files IND for TBS-2025 - grafa.com
TuHURA files IND for TBS-2025 in blood cancer study - Investing.com
TuHURA Biosciences Files Investigational New Drug Application for Evaluation of the TBS-2025 VISTA Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood Related Cancers - PR Newswire
TuHURA Biosciences Q1 2026 Earnings: EPS Misses Estimates, Stock Rises Despite Wider Loss - newsline.com
HURA Q1 2026 Earnings: EPS Misses Estimates Amid Pre-Revenue Stage; Stock Gains 5.29%Margin Expansion Trends - newsline.com
TuHURA Biosciences Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Advances PipelineEarnings Risk Report - newsline.com
TuHURA Biosciences Inc. (HURA) Q1 2026 Earnings: EPS Miss Highlights Pre-Revenue Biotech's Expense Management ChallengesSurprise Factor Analysis - newsline.com
TuHURA Biosciences Inc. (HURA) Q1 2026 Earnings: EPS Misses Estimates Amid Pre-Revenue PhaseMargin Improvement Report - newsline.com
TuHURA Biosciences Inc. (HURA) Q1 2026 Earnings: EPS Misses Estimates, Stock Slides on Higher Cash Burn and Pre-Revenue StatusRevenue Miss Report - newsline.com
HURA News | TUHURA BIOSCIENCES INC (NASDAQ:HURA) - ChartMill
TuHURA Biosciences, Inc. Files Form 8-K with Nasdaq Listing Details and Company Information - Minichart
TuHURA Biosciences Draws on New $50M Credit Facility - TipRanks
TuHURA (NASDAQ: HURA) taps $1.7M from $50M revolving loan facility - Stock Titan
TuHURA Biosciences (HURA) CEO James Bianco gifts 150,000 shares to adult sons - Stock Titan
HURA: Refining TBS-2025 Development Plan - Yahoo Finance
TuHURA Biosciences Inc. (HURA) Rises 6.84% as Price Tests Key Resistance LevelTriangle Correction - newsline.com
TuHURA Biosciences Inc. Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Advances PipelineGuidance vs Actual - newsline.com
TuHURA Biosciences (HURA) Gains Nearly 7% as Shares Approach Key Resistance at $2.62Synthetic Short - Newser
Leverage, Covenants and Royalty Drain: Why Tuhura Biosciences’ Parkview Credit Deal Heightens Liquidity and Dilution Risks - The Globe and Mail
TuHURA Biosciences Secures $50M Credit Facility and Reports Q1 2026 Financial Results, Advancing Phase 3 Immuno-Oncology Programs - Minichart
TuHURA Biosciences Extends Cash Runway and Advances Pipeline - TipRanks
TuHURA Biosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView
TuHURA Biosciences, Inc. 1Q 2026: Revenue $0 Net loss $(7.54M), EPS $(0.13) — 10-Q Summary - TradingView
TuHURA Biosciences (HURA) adds $50M credit line amid $7.5M loss - Stock Titan
TuHURA Biosciences (Nasdaq: HURA) secures $50M credit facility and outlines Q1 2026 pipeline milestones - Stock Titan
TuHURA Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate Update - PR Newswire
TuHURA Biosciences, Inc. (HURA) Eps Diluted (TTM) - Zacks Investment Research
HURA Stock Chart | TUHURA BIOSCIENCES INC (NASDAQ:HURA) - ChartMill
TuHURA Biosciences to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference - ChartMill
TradingKey - TradingKey
TuHURA Biosciences, Inc. (NASDAQ:HURA) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Number of shareholders of TuHURA Biosciences, Inc. – NASDAQ:HURA - TradingView
HURA Stock Price and Chart — NASDAQ:HURA - TradingView
Why TuHURA Biosciences (HURA) is trading below its true worth (Trend Weakens) 2026-05-08Beta Neutral Pair - newsline.com
Tuhura Biosciences, Inc. 2025 Annual Report: Financial Results, Research & Development Expenses, and Key Business Highlights - Minichart
HURA Should I Buy - Intellectia AI
TuHURA Biosciences (NASDAQ: HURA) updates Kineta merger pro forma loss to $34.6M - Stock Titan
TuHURA Biosciences (NASDAQ: HURA) details 2025 loss and cash runway - Stock Titan
HURA TuHURA Biosciences Q4 2025 EPS trails estimates by 28.2 percent, shares slip 1.41 percent in today’s trading. - newsline.com
Citizens initiates TuHURA Biosciences stock with outperform rating By Investing.com - Investing.com South Africa
Citizens initiates TuHURA Biosciences stock with outperform rating - Investing.com
TuHURA Biosciences (NASDAQ:HURA) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
TuHURA Biosciences names Amanda Garofalo as clinical operations SVP By Investing.com - Investing.com Nigeria
Tuhura Biosciences secures $50 million credit facility, extends cash runway to 2028 - MSN
TuHURA Biosciences secures $50M credit facility from affiliate By Investing.com - Investing.com India
HURA (TuHURA Biosciences Inc.) posts 28.2 percent negative Q4 2025 EPS surprise, with shares falling 1.35 percent today.Community Risk Signals - UBND thành phố Hải Phòng
TuHURA Biosciences secures $50M credit facility from affiliate - Investing.com
TuHURA Biosciences Secures $50 Million Credit Facility - TipRanks
TuHURA Biosciences (Nasdaq: HURA) adds $50M credit line and IFx-2.0 royalty - Stock Titan
TuHURA Biosciences Announces $50 Million Credit Facility and Royalty Transaction Extending Anticipated Cash Runway into 2028 - PR Newswire
Tuhura Biosciences Inc (HURA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.60%
0.94%
자본화:
|
볼륨(24시간):